Leadership

Tom Barber, PhD

Tom Barber, PhD

Senior Director, Operations

Dr. Barber has over a decade of microfluidic technology, systems engineering and product development experience in the fields of rare cell isolation and blood separation. As a founding member of the Innovation Team at the Center for Engineering in Medicine at Massachusetts General Hospital, Dr. Barber helped build and lead the engineering team that scaled and disseminated three generations of circulating tumor cell isolation technology.  Prior to joining MGH, Dr. Barber was a key contributor at Verinata Health (acquired by Illumina) in the development of a microfluidic platform for isolating fetal cells from maternal blood. Dr. Barber received his bachelor’s degree from MIT in Materials Science and Engineering, and a Master’s degree in Biomedical Engineering from Northwestern University. He holds a PhD from UC Berkeley/San Francisco’s Joint graduate group in Bioengineering, where he focused on the development of novel orthopedic biomaterial surface coatings. Dr. Barber is a founding team member of MicroMedicine.

Sue Dahlquist

Sue Dahlquist

Vice President, Regulatory Affairs & Quality Assurance

Sue has 25 years of experience in the life sciences and medical device industry including over 15 years in Regulatory Affairs.  Sue’s experience includes successful planning and execution of Global Regulatory Strategies for new product development and regulatory compliance throughout the product lifecycle.  Prior to joining MicroMedicine, Sue held positions at Smith & Nephew, Boston Scientific and Ogranogensis leading regulatory teams in the areas of Cell Therapy, Gynecology, Sports Medicine and Trauma.

Laura Deming, MBA

Laura Deming, MBA

Senior Vice President, Product Development and Manufacturing

Laura brings over 30 years of commercial product development and operations experience, primarily directed at medical device and life science instrumentation integrated with high volume consumables.  This work has included FDA regulated Class II and III therapeutic and diagnostic applications, in addition to research use only.  She has over 15 years of executive level leadership in privately held and publicly traded companies, such as Cytyc (now Hologic), WaveRx, RainDance Technologies, and Columbia Tech.  Prior experience has included roles of increasing responsibility at Millipore (now Merck), and PerSeptive Biosystems/Applied Biosystems (now Thermo Fisher Scientific).  Laura has a BS in Professional Chemistry from Bridgewater State College, an MS in Chemical Engineering from the University of Lowell, and an MBA from Worcester Polytechnic Institute.

Ravi Kapur, PhD

Ravi Kapur, PhD

Co-founder, CEO

Dr. Kapur is a scientist, engineer and entrepreneur with 20 years of experience in developing and commercializing nascent technologies from premier academic laboratories. He has co-founded and built successful innovative companies in partnership with leading academics from Massachusetts General Hospital, MIT and Carnegie Mellon. He co-founded the non-invasive prenatal screening company Verinata Health (acquired by Illumina), and shaped the drug discovery platform at Cellomics (acquired by ThermoFisher).  He co-directs the Innovation Ecosystem at the MGH for development of Microfluidic Platform Technologies for Clinical Medicine.  He earned his master’s degree and doctorate in Bioengineering at Clemson University, with an undergraduate degree in Electrical Engineering from India.  Dr. Kapur has 23 issued and 50 pending US and International patents.

Emre Özkumur, PhD

Emre Özkumur, PhD

Program Manager, Engineering

Dr. Özkumur received his bachelor degree from Koç University, Turkey, double majoring in Electrical and Electronics Engineering and Physics. He completed his Ph.D. in Electrical Engineering, at Boston University’s Photonics Center, where he worked on biophotonics and biosensors. Dr. Ozkumur was recruited to work in the Innovation Team at the Center for Engineering in Medicine of Massachusetts General Hospital. He led a team of highly skilled Engineers, and Technicians, and interfaced with Clinicians to develop a high throughput microfluidic device for isolation of circulating tumor cells from peripheral blood. As project lead, he was accountable to ensure completion of key project milestones driving funding investments from Janssen Diagnostics, LLC. a Johnson & Johnson company. Dr. Ozkumur has experience in leading technical teams and project planning to ensure timely bench-to‐manufacturing transfer of complex and cutting edge technologies. Dr. Özkumur is a founding team member of MicroMedicine.

Nirav (Rav) Sheth, MBA

Nirav (Rav) Sheth, MBA

Vice President, Commercial Development

Rav brings almost 15 years of experience developing and commercializing novel healthcare technologies. His responsibilities have spanned multiple functions, from development to commercial, across multiple disease states, such as cardiovascular and gastrointestinal, and across multiple phases of the healthcare continuum, from interventional to digital remote monitoring. Rav has worked in premier and internationally renowned companies such as McKinsey and Johnson & Johnson as well as privately-owned start-ups such as MC10, a pioneer in clinical wearable sensing. Rav earned a BS in Metallurgical Engineering from Columbia University, an MS in Materials Science from the University of Texas, and an MBA and Master of Engineering Management from Northwestern University.

Kyle Smith, PhD

Kyle Smith, PhD

Director, Research and Development

Dr. Smith is an engineer and scientist with more than a decade of experience in microfluidics, computational modeling, and early-stage medical device development.  While a member of the Innovation Team at Massachusetts General Hospital, he invented and optimized the ultra high-throughput microfluidic cell sorting technologies that lie at the heart of MicroMedicine’s products.  He also led a team in developing novel, extremely high sensitivity devices for isolating and analyzing circulating tumor cells, among many other early-stage R&D projects.  Dr. Smith received his bachelor’s degree in Biomedical Engineering from Duke University, his master’s in Electrical Engineering and Computer Science from MIT, and his PhD in Biomedical and Electrical Engineering from the Harvard-MIT Division of Health Sciences and Technology, where he held prestigious fellowships from the National Science Foundation, Whitaker Foundation, and MIT. His doctoral work focused on the development of sophisticated computational models of electroporation and molecular transport with applications in drug delivery, cancer treatment, and biotechnology.  Dr. Smith is a founding team member of MicroMedicine.